NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.
You may also be interested in...
U.K’s NICE To Help Build India’s Health Technology Assessment Board
India is seeking scientific tools like health technology assessments from the United Kingdom’s National Institute for Health Care Excellence as it braces for wider health care coverage and implements a new drug pricing policy.
Roche Experimenting With New Pricing Models In Oncology
Cancer drug prices are unsustainable and creative approaches are needed, Roche’s COO Daniel O’Day says. The firm’s moves into emerging markets are a lab for new methods, though the real test will come as the more expensive drugs are used in combination.
Roche Experimenting With New Pricing Models In Oncology
Cancer drug prices are unsustainable and creative approaches are needed, Roche’s O’Day says. The firm’s moves into emerging markets are a lab for new methods, he said, though the real test will come as the more expensive drugs are used in combination.